NCT02689882View on ClinicalTrials.gov

"Pharmacokinetic Study of Nicotinamide Riboside"

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
Metabolic Disturbance
Interventions
DIETARY_SUPPLEMENT

nicotinamide riboside

Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Washington

OTHER

NCT02689882 - "Pharmacokinetic Study of Nicotinamide Riboside" | Biotech Hunter | Biotech Hunter